Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 15/20 | 0.84 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.84 |
| ▸ | ITGAL | P20701 | 15/20 | 0.84 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21194988 | 1.00 | ITGB2 (0.84) | ITGB2ICAM1ITGALNPC1RAB9A | |
| SCHEMBL11949519 | 0.89 | ITGB2 (0.85) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL23092632 | 0.84 | ITGB2 (0.81) | ITGB2ICAM1ITGALERAP2 | |
| SCHEMBL11874268 | 0.84 | ITGB2 (0.81) | ITGB2ICAM1ITGALERAP2 | |
| SCHEMBL16599700 | 0.84 | ITGB2 (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL16599702 | 0.84 | ITGB2 (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL21623656 | 0.84 | ITGB2 (1.00) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL21623657 | 0.84 | ITGB2 (1.00) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL15145360 | 0.82 | ITGB2 (0.74) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL30081478 | 0.82 | ITGB2 (0.74) | ITGB2ICAM1ITGALALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374027-B1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | UNIV COLUMBIA (US) | 2021-06-23 | — | — | EP | claimed |
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-08-01 | — | — | US | claimed |
| EP-3374027-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | The Trustees of Columbia University in the City of New York (US) | 2018-09-19 | — | — | EP | claimed |
| WO-2017083859-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-18 | — | — | WO | claimed |
| EP-3374027-B1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | UNIV COLUMBIA (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10925857-B2 | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-08-01 | — | — | US | disclosed |
| EP-3374027-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | The Trustees of Columbia University in the City of New York (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017083859-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | APRT, NMT2, NMT1 | ITGB2 2649/4885ICAM1 4210/4885ITGAL 3631/4885 |
| US-10925857-B2 | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics | APRT, NMT2, NMT1 | ITGB2 2649/4885ICAM1 4210/4885ITGAL 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.